spacer
home > ebr > summer 2002 > technology appraisal process and presents the facts behind the nice appraisal of beta-interferon
PUBLICATIONS
European Biopharmaceutical Review

Technology Appraisal Process and presents the facts behind the NICE appraisal of beta-interferon

The National Institute for Clinical Excellence (NICE or the Institute) is part of the NHS. It provides guidance for the NHS, its patients and their carers about treatment and health care. The guidance on beta-interferon and glatiramer acetate was a part of the technology appraisals work programme. Appraisals are independent considerations of both the clinical and cost effectiveness of health technologies. Topics include medicines, medical devices, diagnostic techniques, surgical procedures and health promotion activities. The Secretary of State for Health and the Welsh Assembly Government decide which topics NICE will appraise. However, once the technology has been referred to NICE, the development of the guidance is the responsibility of NICE alone.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Anne-Toni Rodgers, Communications Director of the National Institute for Clinical Excellence (NICE)

Anne-Toni Rodgers is a pharmacology graduate with a strong track record in communications with the NHS, industry and patients. Prior to joining the Institute, she spent 18 years in a variety of roles for the pharmaceutical industry including pure research, regulatory affairs, sales and marketing and government and industry affairs.
She is a graduate of the Common Purpose Programme, Vice-Chair of the London region of the Institute for Health Service Management, an editorial board member for the Journal of Quality in Healthcare and an advisory board member for the Association of Quality in Healthcare. Anne-Toni acts as an executive lead on both technology appraisals and clinical guidelines, and is a member of the management board of the National Prescribing Centre. She holds responsibility for the communication and dissemination of the Institute's work to all stakeholders. Anne-Toni joined the National Institute for Clinical Excellence on 12th July 1999.

spacer
Anne-Toni Rodgers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement